Results 51 to 60 of about 853 (171)

Novel Promising Antifungal Target Proteins for Conquering Invasive Fungal Infections

Frontiers in Microbiology, 2022
Invasive fungal infections (IFIs) pose a serious clinical problem, but the antifungal arsenal is limited and has many disadvantages, such as drug resistance and toxicity.
Cheng Zhen, Hui Lu, Yuanying Jiang
doaj   +1 more source

Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review

Journal of Fungi, 2022
The alarming spread and impact of multidrug-resistant Candida auris infections alongside the limited therapeutic options have prompted the development of new antifungals.
Rogelio de J. Treviño-Rangel, Gloria M. González, Alexandra M. Montoya, Olga C. Rojas, Mariana Elizondo-Zertuche, Neri A. Álvarez-Villalobos   +5 more
doaj   +1 more source

Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus [PDF]

Antimicrobial Agents and Chemotherapy, 2018
F901318 (olorofim) is a novel antifungal drug that is highly active against Aspergillus species. Belonging to a new class of antifungals called the orotomides, F901318 targets dihydroorotate dehydrogenase (DHODH) in the de novo pyrimidine biosynthesis pathway.
du Pré, Saskia, Beckmann, Nicola, Almeida, Mariana Cruz, Sibley, Graham E M, Law, Derek, Brand, Alexandra C, Birch, Mike, Read, Nick D, Oliver, Jason D   +8 more
openaire   +3 more sources

Inhibition of azole-resistant Aspergillus fumigatus biofilm at various formation stages by antifungal drugs, including olorofim

Journal of Antimicrobial Chemotherapy, 2022
Abstract Objectives Interest in aspergillosis has increased over the past decades. An increase in the incidence of azole-resistant Aspergillus fumigatus strains has been reported; therefore, the need for novel therapeutic approaches is urgent.
Lisa Kirchhoff, Silke Dittmer, Dan-Tiberiu Furnica, Jan Buer, Eike Steinmann, Peter-Michael Rath, Joerg Steinmann   +6 more
openaire   +3 more sources

Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma.

PLoS Neglected Tropical Diseases, 2022
Eumycetoma is a chronic subcutaneous neglected tropical disease that can be caused by more than 40 different fungal causative agents. The most common causative agents produce black grains and belong to the fungal orders Sordariales and Pleosporales.
Wilson Lim, Bertrand Nyuykonge, Kimberly Eadie, Mickey Konings, Juli Smeets, Ahmed Fahal, Alexandro Bonifaz, Matthew Todd, Benjamin Perry, Kirandeep Samby, Jeremy Burrows, Annelies Verbon, Wendy van de Sande   +12 more
doaj   +1 more source

Acute Lymphoblastic Leukemia and Invasive Mold Infections: A Challenging Field

Journal of Fungi, 2022
Acute lymphoblastic leukemia (ALL) patients comprise a highly immunocompromised group due to factors associated either with the treatment or the disease itself.
Christos Stafylidis, Panagiotis Diamantopoulos, Eleni Athanasoula, Elena Solomou, Amalia Anastasopoulou   +4 more
doaj   +1 more source

Management of Invasive Pulmonary Aspergillosis in Intensive Care Units: Guidelines From the Fungal Infection Network of Switzerland (FUNGINOS)

Mycoses, Volume 68, Issue 11, November 2025.
ABSTRACT Invasive pulmonary aspergillosis (IPA) is increasingly recognised in intensive care units (ICU) affecting not only patients with classical immunosuppressive conditions but also other severely ill patients, including those with respiratory viral infections (influenza, COVID‐19), advanced chronic obstructive pulmonary disease or acute and ...
F. Lamoth, W. C. Albrich, S. Ragozzino, D. Bosetti, J. Delaloye, C. El Khoury, A. Munting, V. Portillo, I. Reinhold, J. Sumer, A. Zbinden, V. Bättig, C. Beigelman‐Aubry, K. Boggian, A. Conen, T. S. Fischer, C. Garzoni, D. Goldenberger, E. Hofmann, P. Khafagy, L. Kern, G. R. Kleger, C. Le Terrier, O. Marchetti, J. L. Pagani, N. J. Rupp, P. W. Schreiber, M. Siegemund, F. Kadgien, D. Neofytos, N. Khanna, on behalf of the Fungal Infection Network of Switzerland (FUNGINOS), Werner Albrich, Christoph Berger, Anne Bergeron, Sabina Berezowska, Pierre‐Yves Bochud, Katia Boggian, Anna Conen, Julie Delaloye, Stéphane Emonet, Véronique Erard, Christian Garzoni, Daniel Goldenberger, Vladimira Hinic, Cedric Hirzel, Eleftheria Evdokia Kampouri, Nina Khanna, Malte Kohns, Andreas Kronenberg, Frederic Lamoth, Basile Landis, Oscar Marchetti, Konrad Mühlethaler, Linda Müller, Dionysios Neofytos, Michael Osthoff, Jean‐Luc Pagani, Chantal Quiblier, Arnaud Riat, Niels Rupp, Bettina Schulthess, Peter Werner Schreiber, Martin Siegemund, Laura Walti   +64 more
wiley   +1 more source

The Role of Olorofim in the Treatment of Filamentous Fungal Infections: A Review of In Vitro and In Vivo Studies

Journal of Fungi
Invasive fungal infections have recently been recognized by the WHO as a major health, epidemiological, and economic issue. Their high mortality rates and the emergence of drug resistance have driven the development of new molecules, including olorofim ...
Aliosha Feuss, Marie-Elisabeth Bougnoux, Eric Dannaoui   +2 more
doaj   +1 more source

Terapêutica antifúngica: novas moléculas, novas formas de administração e diferentes estratégias para alcançar a toxicidade seletiva [PDF]

, 2021
Nos últimos anos verificou-se um aumento das infeções fúngicas invasivas, devido ao aumento da esperança de vida e do número de doentes imunodeprimidos e ao aparecimento de resistência aos antifúngicos.
Moreira, Marta Alexandra Macedo
core  

The Changing Epidemiology of Breakthrough Invasive Fungal Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the Era of Modified‐Release Posaconazole Prophylaxis

Transplant Infectious Disease, Volume 27, Issue 6, November/December 2025.
This single‐center retrospective cohort study on 300 allogeneic hematopoietic stem cell transplant recipients from January 2017 to May 2020, in which posaconazole modified release was the most common primary antifungal prophylaxis, demonstrated a breakthrough invasive fungal disease (bIFD) rate of 9%, with associated significant all‐cause mortality at ...
Shio Yen Tio, Chin Fen Neoh, David Ritchie, Lynette Chee, David C. M. Kong, Leon J. Worth, Michelle K. Yong, Monica A. Slavin   +7 more
wiley   +1 more source